



Board of Pharmacy Adds Nalmefene as an Overdose Reversal Drug - Effective 10/31/23

On October 31, 2023, nalmefene (\underline{OPVEE}) will be added as an overdose reversal drug (ORD) per OAC $\underline{4729}$ -8-01. By classifying nalmefene as an ORD, it can be distributed in the same manner as naloxone.

To assist Ohioans in understanding laws governing the distribution of overdose reversal drugs, the State of Ohio Board of Pharmacy developed a comprehensive guide, which can be accessed here: www.pharmacy.ohio.gov/ORD.

Please note that if you choose to unsubscribe from receiving emails, this unsubscribes you from all emails that are sent by the State of Ohio Board of Pharmacy, including renewal reminders. If you believe you have unsubscribed in error, you may subscribe by visiting: <u>www.pharmacy.ohio.gov/subscribe</u>. If you would like to change the email address, please log into your eLicense Ohio account to update the email address on file.